Page 149 - ITPS-7-2
P. 149

INNOSC Theranostics and
            Pharmacological Sciences                                                Dapsone enhance skin flap survival



            46.  Modschiedler K, Weller M, Wörl P, von den Driesch P.   Sci. 2018;19(6):744-749.
               Dapsone and colchicine inhibit adhesion of neutrophilic      doi: 10.4142/jvs.2018.19.6.744
               granulocytes to epidermal sections.  Arch Dermatol Res.
               2000;292(1):32-36.                              57.  Nezamoleslami S, Sheibani M, Jahanshahi F, Mumtaz F,
                                                                  Abbasi A, Dehpour AR. Protective effect of dapsone against
               doi: 10.1007/pl00007458                            renal ischemia-reperfusion injury in rat. Immunopharmacol
            47.  Suda T, Suzuki Y, Matsui T,  et al. Dapsone suppresses   Immunotoxicol. 2020;42(3):272-279.
               human neutrophil superoxide production and elastase      doi: 10.1080/08923973.2020.1755308
               release in a calcium-dependent manner.  Br J Dermatol.
               2005;152(5):887-895.                            58.  Sheibani M, Nezamoleslami S, Faghir-Ghanesefat H,
                                                                  Emami  AH, Dehpour AR. Cardioprotective effects of
               doi: 10.1111/j.1365-2133.2005.06559.x              dapsone against doxorubicin-induced cardiotoxicity in rats.
            48.  Zalewska A, Napieralska-Krzysiek E. [Dapsone in skin   Cancer Chemother Pharmacol. 2020;85(3):563-571.
               diseases]. Pol Merkur Lekarsk. 2003;15(89):484-486.     doi: 10.1007/s00280-019-04019-6
            49.  Khalilzadeh M, Shayan M, Jourian S, Rahimi M, Sheibani M,   59.  Kast RE, Lefranc F, Karpel-Massler G, Halatsch ME. Why
               Dehpour AR. A  comprehensive insight into the anti-  dapsone stops seizures and may stop neutrophils’ delivery of
               inflammatory properties of dapsone. Naunyn Schmiedebergs   VEGF to glioblastoma. Br J Neurosurg. 2012;26(6):813-817.
               Arch Pharmacol. 2022;395(12):1509-1523.
                                                                  doi: 10.3109/02688697.2012.674577
               doi: 10.1007/s00210-022-02297-1
                                                               60.  Kast RE. Dapsone as treatment adjunct in ARDS. Exp Lung
            50.  Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus    Res. 2020;46(5):157-161.
               erythematosus: Update of therapeutic options part II. J Am
               Acad Dermatol. 2011;65(6):e195-e213.               doi: 10.1080/01902148.2020.1753266
                                                               61.  Kast  RE,  Hill  QA,  Wion  D,  et al.  Glioblastoma-
               doi: 10.1016/j.jaad.2010.06.017
                                                                  synthesized G-CSF and GM-CSF contribute to growth
            51.  Stannard JN, Kahlenberg JM. Cutaneous lupus      and immunosuppression: Potential therapeutic benefit
               erythematosus:  Updates  on  pathogenesis  and     from  dapsone,  fenofibrate,  and  ribavirin.  Tumour Biol.
               associations with systemic lupus. Curr Opin Rheumatol.   2017;39(5):1010428317699797.
               2016;28(5):453-459.
                                                                  doi: 10.1177/1010428317699797
               doi: 10.1097/bor.0000000000000308
                                                               62.  Qian  LW,  Fourcaudot  AB,  Yamane  K,  You  T,  Chan  RK,
            52.  Kozub P, Simaljakova M. Hidradenitis suppurativa treated   Leung KP. Exacerbated and prolonged inflammation impairs
               with combination of infliximab and dapsone.  Bratisl Lek   wound healing and increases scarring. Wound Repair Regen.
               Listy. 2012;113(5):319-323.                        2016;24(1):26-34.
               doi: 10.4149/bll_2012_074                          doi: 10.1111/wrr.12381
            53.  Geyfman M, Debabov D, Poloso N, Alvandi N. Mechanistic   63.  Ellis S, Lin EJ, Tartar D. Immunology of wound healing.
               insight into the activity of a sulfone compound dapsone on   Curr Dermatol Rep. 2018;7(4):350-358.
               Propionibacterium (Newly Reclassified as  Cutibacterium)      doi: 10.1007/s13671-018-0234-9
               Acnes-mediated cytokine production.  Exp Dermatol.
               2019;28(2):190-197.                             64.  Harder Y, Amon M, Laschke M,  et al. An old dream
                                                                  revitalised: Preconditioning strategies to protect surgical
               doi: 10.1111/exd.13869                             flaps from critical ischaemia and ischaemia-reperfusion
            54.  Köstler  E,  Wollina U.  Ulcerated necrobiosis lipoidica:   injury. J Plast Reconstr Aesthet Surg. 2008;61(5):503-511.
               A combined treatment approach with dermatosurgery and      doi: 10.1016/j.bjps.2007.11.032
               PUVA. Int J Low Extrem Wounds. 2003;2(4):243-245.
                                                               65.  Hosnuter M, Babucçu O, Kargi E, Altinyazar C. Dual
               doi: 10.1177/1534734603260680                      preconditioning: Effects of pharmacological plus ischemic
            55.  Erfurt-Berge C, Heusinger V, Reinboldt-Jockenhöfer F,   preconditioning on skin flap survival.  Ann Plast Surg.
               Dissemond J, Renner R. Comorbidity and therapeutic   2003;50(4):398-402.
               approaches in patients with necrobiosis lipoidica.      doi: 10.1097/01.SAP.0000037261.84618.7F
               Dermatology. 2022;238:148-155.
                                                               66.  Gözü A,  Poda M, Taskin EI,  et al. Pretreatment with
               doi: 10.1159/000514687                             octreotide modulates iNOS gene expression, mimics
            56.  Kwon MJ, Joo HG. Dapsone modulates lipopolysaccharide-  surgical delay, and improves flap survival. Ann Plast Surg.
               activated bone marrow cells by inducing cell death and   2010;65(2):245-249.
               down-regulating tumor necrosis factor-α production. J Vet   doi: 10.1097/SAP.0b013e3181c1fe8f


            Volume 7 Issue 2 (2024)                         12                               doi: 10.36922/itps.2241
   144   145   146   147   148   149   150   151   152   153   154